158 related articles for article (PubMed ID: 33893156)
1. Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case-control study.
Klein MN; Wang EW; Zimand P; Beauchamp H; Donis C; Ward MD; Martinez-Hernandez A; Tabatabai A; Baddley JW; Bloch EM; Mullins KE; Fontaine MJ
J Clin Pathol; 2022 Aug; 75(8):564-571. PubMed ID: 33893156
[TBL] [Abstract][Full Text] [Related]
2. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
Front Immunol; 2021; 12():739037. PubMed ID: 34594341
[TBL] [Abstract][Full Text] [Related]
3. Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light.
Larrea L; Castro E; Navarro L; Vera B; Francés-Gómez C; Sánchez-Sendra B; Giménez Á; Castelló E; Collado M; Vayá MJ; Mirabet V; Callao V; Ortiz-de-Salazar MI; Roig R; Geller R; Arbona C
Blood Transfus; 2022 May; 20(3):206-212. PubMed ID: 34369870
[TBL] [Abstract][Full Text] [Related]
4. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
5. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.
Madariaga MLL; Guthmiller JJ; Schrantz S; Jansen MO; Christensen C; Kumar M; Prochaska M; Wool G; Durkin-Celauro A; Oh WH; Trockman L; Vigneswaran J; Keskey R; Shaw DG; Dugan H; Zheng NY; Cobb M; Utset H; Wang J; Stovicek O; Bethel C; Matushek S; Giurcanu M; Beavis KG; di Sabato D; Meltzer D; Ferguson MK; Kress JP; Shanmugarajah K; Matthews JB; Fung JF; Wilson PC; Alverdy JC; Donington JS
J Intern Med; 2021 Apr; 289(4):559-573. PubMed ID: 33034095
[TBL] [Abstract][Full Text] [Related]
6. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM
Trials; 2021 May; 22(1):323. PubMed ID: 33947446
[TBL] [Abstract][Full Text] [Related]
7. Convalescent plasma in hospitalized pediatric and obstetric coronavirus disease 2019 (COVID-19) patients.
Ikeda S; Benzi E; Hensch LA; Devaraj S; Hui SR; Gandhi M; Fox KA; Teruya J; Munoz FM
Pediatr Int; 2022 Jan; 64(1):e15407. PubMed ID: 36326636
[TBL] [Abstract][Full Text] [Related]
8. Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients.
Arrieta A; Galvis AE; Morphew T; Ehwerhemuepha L; Osborne S; Enriquez C; Imfeld K; Hoang J; Nieves D; Ashouri N; Singh J; Nugent D
Pediatr Infect Dis J; 2021 Jul; 40(7):606-611. PubMed ID: 33967228
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors.
Leon J; Merrill AE; Rogers K; Kurt J; Dempewolf S; Ehlers A; Jackson JB; Knudson CM
Transfus Apher Sci; 2022 Apr; 61(2):103326. PubMed ID: 34862140
[TBL] [Abstract][Full Text] [Related]
10. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection.
Clark NM; Janaka SK; Hartman W; Stramer S; Goodhue E; Weiss J; Evans DT; Connor JP
PLoS One; 2022; 17(3):e0257930. PubMed ID: 35259162
[TBL] [Abstract][Full Text] [Related]
11. Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial.
Park HS; Yin A; Barranta C; Lee JS; Caputo CA; Sachithanandham J; Li M; Yoon S; Sitaras I; Jedlicka A; Eby Y; Ram M; Fernandez RE; Baker OR; Shenoy AG; Mosnaim GS; Fukuta Y; Patel B; Heath SL; Levine AC; Meisenberg BR; Spivak ES; Anjan S; Huaman MA; Blair JE; Currier JS; Paxton JH; Gerber JM; Petrini JR; Broderick PB; Rausch W; Cordisco ME; Hammel J; Greenblatt B; Cluzet VC; Cruser D; Oei K; Abinante M; Hammitt LL; Sutcliffe CG; Forthal DN; Zand MS; Cachay ER; Raval JS; Kassaye SG; Marshall CE; Yarava A; Lane K; McBee NA; Gawad AL; Karlen N; Singh A; Ford DE; Jabs DA; Appel LJ; Shade DM; Lau B; Ehrhardt S; Baksh SN; Shapiro JR; Ou J; Na YB; Knoll MD; Ornelas-Gatdula E; Arroyo-Curras N; Gniadek TJ; Caturegli P; Wu J; Ndahiro N; Betenbaugh MJ; Ziman A; Hanley DF; Casadevall A; Shoham S; Bloch EM; Gebo KA; Tobian AA; Laeyendecker O; Pekosz A; Klein SL; Sullivan DJ
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38483534
[TBL] [Abstract][Full Text] [Related]
12. Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment.
Karaba AH; Johnston TS; Beck E; Laeyendecker O; Cox AL; Klein SL; Sullivan DJ;
mBio; 2023 Feb; 14(1):e0328722. PubMed ID: 36625657
[TBL] [Abstract][Full Text] [Related]
13. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19.
Sanz C; Nomdedeu M; Pereira A; Sauleda S; Alonso R; Bes M; Brillembourg H; García-Vidal C; Millan A; Martínez-Llonch N; Pirón M; Puerta-Alcalde P; Puig L; Rico V; Soriano A
Transfusion; 2022 May; 62(5):974-981. PubMed ID: 35338710
[TBL] [Abstract][Full Text] [Related]
15. Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.
Weisser M; Khanna N; Hedstueck A; Sutter ST; Roesch S; Stehle G; Sava M; Deigendesch N; Battegay M; Infanti L; Holbro A; Bassetti S; Pargger H; Hirsch HH; Leuzinger K; Kaiser L; Vu DL; Baur K; Massaro N; Busch MP; Simmons G; Stone M; Felgner PL; de Assis RR; Khan S; Tsai CT; Robinson PV; Seftel D; Irsch J; Bagri A; Buser AS; Corash L
Transfusion; 2022 Oct; 62(10):1997-2011. PubMed ID: 36054476
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
17. Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology.
Yonemura S; Hartson L; Dutt TS; Henao-Tamayo M; Goodrich R; Marschner S
Vox Sang; 2021 Nov; 116(10):1076-1083. PubMed ID: 33835489
[TBL] [Abstract][Full Text] [Related]
18. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
[TBL] [Abstract][Full Text] [Related]
19. Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme-The South African Experience.
Glatt TN; Hilton C; Nyoni C; Swarts A; Swanevelder R; Cowley J; Mmenu C; Moyo-Gwete T; Moore PL; Kutama M; Jaza J; Phayane I; Brits T; Koekemoer J; Jentsch U; Nelson D; van den Berg K; Vermeulen M
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696480
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
